Ocular Therapeutix, Inc. (OCUL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$10.640.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · OCUL
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 146.3% |
| Our one-year growth estimate | diamond | 64.5% |
Growth built into the price is above our model estimate.
The price assumes 81.8 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
OCUL — earnings miss
Dated 2026-05-05
Results of Operations and Financial Condition. On May 5, 2026, Ocular Therapeutix, Inc. announced its financial results for the quarter ended March 31, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with
Why it matters: Being ready for the market is key for AXPAXLI's launch if it gets approved.
Supportive ifOcular completes key market and payer research ahead of the potential 2027 launch.
Worry ifCommercial readiness activities slow down or do not make real progress.
Why it matters: Management wants to make more money. This progress is key for investor trust.
Supportive ifNet income improves to less than $(80) million. Revenue goes over $12 million soon.
Worry ifNet income drops further below $(88.6) million. Revenue stays under $10 million.
Why it matters: Watching the cash balance is important. It affects Ocular's ability to fund operations and trials until 2028.
Worry ifThe cash balance is enough to support operations until 2028.
Less concerning ifThe cash balance is much lower than expected, which raises funding concerns.
Why it matters: Updates on readiness show how ready Ocular is for a launch. Good readiness can help it succeed in the market.
Supportive ifManagement says they are making progress on AXPAXLI. It may launch in 2027.
Worry ifCommercial readiness may slow down. Key stakeholders are not very involved.
Why it matters: Better financial results may show that AXPAXLI is more accepted in the market.
Supportive ifQ2 net revenue shows an increase from $10.8 million in Q1 2026.
Worry ifQ2 net revenue declines or remains flat compared to Q1 2026.
Why it matters: Financial updates will show if Ocular is making more money and cutting losses. This is key for investor trust.
Worry ifQ2 earnings show revenue growth or reduced losses compared to Q1.
Less concerning ifThe Q2 earnings report shows more drops in revenue or bigger losses.
Why it matters: Enrollment in SOL-X could give more safety data for AXPAXLI. This may help its market chance.
Supportive ifEnrollment in the SOL-X trial reaches the target number of participants.
Worry ifEnrollment in the SOL-X trial is slower than expected. This may show possible problems.
Why it matters: Results from the SOL-X trial may show long-term benefits of AXPAXLI.
Watch forPositive outcomes from the SOL-X trial that support early treatment with AXPAXLI.
Also watch forNegative results from the SOL-X trial raise doubts about how well the treatment works.
Why it matters: Cash balance updates will show if Ocular can keep funding until 2028.
Worry ifCash balance remains above $598.6 million as of Q3 2026.
Less concerning ifCash balance falls significantly below $598.6 million by Q3 2026.
Why it matters: The NDA submission is a key step toward potential approval of AXPAXLI. This could lead to a new treatment option for wet AMD patients.
Supportive ifNDA submission for AXPAXLI is confirmed for Q4 2026 based on SOL-1 data.
Worry ifNDA submission is delayed beyond Q4 2026.
Why it matters: Results from SOL-R will give more data for AXPAXLI's market entry. Good results could help it gain users.
Supportive ifTopline data from the SOL-R trial is on track for Q1 2027.
Worry ifTopline data from SOL-R is significantly delayed beyond Q1 2027.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$220 on $10,000 · ±2.2% | How much price usually moves either way. |
| Bad day | $655 loss on $10,000 · 6.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,729 loss on $10,000 · 57.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.